仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002332 仙琚制药

交易中 01-23 11:07:27

{"stockData":{"symbol":"002332","market":"SZ","secType":"STK","nameCN":"仙琚制药","latestPrice":9.36,"timestamp":1769137647000,"preClose":9.36,"halted":0,"volume":7148067,"delay":0,"changeRate":0,"floatShares":985000000,"shares":989000000,"eps":0.2767,"marketStatus":"交易中","change":0,"latestTime":"01-23 11:07:27","open":9.37,"high":9.42,"low":9.35,"amount":67060800,"amplitude":0.0075,"askPrice":9.37,"askSize":1186,"bidPrice":9.36,"bidSize":894,"shortable":0,"etf":0,"ttmEps":0.2767,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1769139000000},"marketStatusCode":2,"adr":0,"adjPreClose":9.36,"symbolType":"stock","openAndCloseTimeList":[[1769131800000,1769139000000],[1769144400000,1769151600000]],"highLimit":10.3,"lowLimit":8.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":989204866,"isCdr":false,"pbRate":1.55,"roa":"--","peRate":33.82725,"roe":"6.8%","epsLYR":0.4,"committee":-0.032678,"marketValue":9259000000,"turnoverRate":0.0073,"status":2,"floatMarketCap":9216000000},"requestUrl":"/m/hq/s/002332","defaultTab":"news","newsList":[{"id":"2605235871","title":"仙琚制药：阿更葡糖钠注射液尚在评审阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2605235871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605235871?lang=zh_cn&edition=full","pubTime":"2026-01-21 08:42","pubTimestamp":1768956128,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药01月20日在投资者关系平台上答复投资者关心的问题。目前该产品尚在评审阶段，该产品能否获批以及获批时间尚存在不确定性，且获批后的市场准入，医保国谈等事宜的进程和结果亦存在较大的不确定性，敬请广大投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100006105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SG9999014674.SGD","BK0028","002332"],"gpt_icon":0},{"id":"2605148262","title":"股市必读：仙琚制药（002332）1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605148262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605148262?lang=zh_cn&edition=full","pubTime":"2026-01-21 01:57","pubTimestamp":1768931827,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，仙琚制药报收于9.42元，上涨0.21%，换手率1.24%，成交量12.22万手，成交额1.15亿元。董秘最新回复投资者： 请问1月10日公司股东人数是多少？截止近期，公司股东约5万户。仙琚制药和杭州奥默签署的里程碑分成协议、商业化销售分成协议、原料药供应及制剂委托加工协议，明确了今后该产品获批后商业化阶段的收益分配机制和供应保障机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100000852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002332","SG9999014674.SGD"],"gpt_icon":0},{"id":"2604195522","title":"仙琚制药：奥美克松钠尚在评审阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2604195522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604195522?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:03","pubTimestamp":1768899799,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药01月20日在投资者关系平台上答复投资者关心的问题。仙琚制药和杭州奥默签署的里程碑分成协议、商业化销售分成协议、原料药供应及制剂委托加工协议，明确了今后该产品获批后商业化阶段的收益分配机制和供应保障机制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000026127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","002332","BK0028","BK0239"],"gpt_icon":0},{"id":"2603399405","title":"仙琚制药（002332）披露签订共同授权合作产品中国境内推广服务商三方协议，1月16日股价下跌1.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603399405","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603399405?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:47","pubTimestamp":1768574829,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，仙琚制药报收于9.26元，较前一交易日下跌1.38%，最新总市值为91.6亿元。近日，浙江仙琚制药股份有限公司与杭州奥默医药股份有限公司、爱施健（广东）制药有限公司签订三方协议，共同授权爱施健公司作为阿更葡糖钠注射液在中国境内的独家市场推广服务商。同时，仙琚制药与杭州奥默签署多项协议，明确该产品商业化里程碑分成、销售收益分成、原料药采购及制剂委托生产等安排。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","SG9999014674.SGD","BK0028","BK0239"],"gpt_icon":0},{"id":"2603964827","title":"仙琚制药最新公告：签订1.1类新药阿更葡糖钠注射液相关协议与杭州奥默商业化里程碑分成比例为各50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603964827","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603964827?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:51","pubTimestamp":1768557079,"startTime":"0","endTime":"0","summary":"仙琚制药与杭州奥默于2026年1月16日签订了《阿更葡糖钠注射液中国境内商业化里程碑分成协议》、《阿更葡糖钠注射液中国境内商业化销售收益分成协议》，约定未来该产品的商业化里程碑分成比例为双方各50%；商业化销售收益分成比例为：中国境内商业化收益扣除相应费用后的净收益，由仙琚制药和杭州奥默双方对半分享，各占商业化销售后净收益的50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600029525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","SG9999014674.SGD","BK0239"],"gpt_icon":0},{"id":"2601363971","title":"仙琚制药最新公告：取得倍他米松磷酸钠注射液境内生产药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363971","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363971?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:01","pubTimestamp":1767870077,"startTime":"0","endTime":"0","summary":"仙琚制药(002332.SZ)公告称，公司近日收到国家药品监督管理局核准签发的倍他米松磷酸钠注射液的《药品注册证书》，该药品被批准注册。倍他米松磷酸钠注射液主要用于需要使用糖皮质激素治疗的疾病，公司取得该药品的境内生产药品注册证书，有利于丰富公司产品线，提升市场竞争力。但需注意药品研发、生产和销售受政策、市场环境等因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800032366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2592975331","title":"仙琚制药(002332.SZ)：雌二醇片/雌二醇地屈孕酮片复合包装药品注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975331","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592975331?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:12","pubTimestamp":1766045556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仙琚制药(002332.SZ)公告，公司近日收到国家药品监督管理局下发的雌二醇片/雌二醇地屈孕酮片复合包装境内生产药品注册受理通知书。本次公司申报的雌二醇片/雌二醇地屈孕酮片复合包装规格与原研已批准上市的规格一致，按化学药品4类进行申报。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"仙琚制药(002332.SZ)：雌二醇片/雌二醇地屈孕酮片复合包装药品注册申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","BK0028","002332","BK0239"],"gpt_icon":0},{"id":"2592960605","title":"仙琚制药：该产品近期已递交相关制剂及原料药补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2592960605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592960605?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:24","pubTimestamp":1765959887,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药(002332)12月17日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好：请问贵公司与奥默医药共同研发的新药奥美克松纳是已经完成药审中心补充资料，如果没有预计什么时候可以完成？感谢你在百忙之中给予详细的解答！仙琚制药回复：尊敬的投资者，您好！感谢您对公司的关注。据了解该产品近期已递交相关制剂及原料药补充资料，敬请投资者注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700022482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0028","BK0239","002332"],"gpt_icon":0},{"id":"2590431119","title":"仙琚制药(002332.SZ)：盐酸尼卡地平注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2590431119","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590431119?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:23","pubTimestamp":1765272224,"startTime":"0","endTime":"0","summary":"智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于盐酸尼卡地平注射液的《药品补充申请批准通知书》(通知书编号：2025B05803和2025B05804)，公司盐酸尼卡地平注射液通过仿制药质量和疗效一致性评价。盐酸尼卡地平注射液是一种钙离子拮抗剂药物，主要用于快速降低血压和处理急性高血压情况，如手术中或急诊环境。它通过扩张血管来促进血流，保护心、脑、肾等重要器官，效果迅速但需在医生监控下使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002332","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2589872335","title":"仙琚制药：截止近期公司股东约5万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2589872335","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589872335?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:57","pubTimestamp":1765184232,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药(002332)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2025年11月30日，公司股东人数是多少？仙琚制药回复：您好，感谢您的关注。截止近期，公司股东约5万户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800019900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2589335805","title":"仙琚制药：黄体酮阴道缓释凝胶需补充临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589335805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589335805?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:57","pubTimestamp":1765184226,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药12月08日在投资者关系平台上答复投资者关心的问题。关注到公司申报的黄体酮阴道缓释凝胶已在CDE完成各项审评，即将成为这个10亿品种的首仿药物！据了解该产品尚未获批，需要进一步补充孕激素浓度和生物学效应相关指标的对比临床研究数据。复杂制剂及新药研发具有不确定性，敬请投资者注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800019898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0028","002332","BK0239"],"gpt_icon":0},{"id":"2588646098","title":"仙琚制药：构建内控管理制度防范职务侵占","url":"https://stock-news.laohu8.com/highlight/detail?id=2588646098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588646098?lang=zh_cn&edition=full","pubTime":"2025-12-03 09:06","pubTimestamp":1764723968,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药12月02日在投资者关系平台上答复投资者关心的问题。公司制定了涵盖经营决策、财务管控、资产处置、关联交易、人员管理等领域的内控管理制度，明确管理层履职边界与禁止性规定，从制度层面杜绝违规行为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300004719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","SG9999014674.SGD","BK0028","BK0239"],"gpt_icon":0},{"id":"2586070012","title":"仙琚制药：公司市值管理工作由董事会领导","url":"https://stock-news.laohu8.com/highlight/detail?id=2586070012","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586070012?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:00","pubTimestamp":1764320448,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药(002332)11月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好公司市值管理制度考核是由当地国资监管部门负责的吗？仙琚制药回复：尊敬的投资者您好！公司市值管理工作由董事会领导，公司大股东、实际控制人可以对市值管理工作提出建议和措施。市值管理工作需要结合公司自身发展阶段、行业发展趋势、资本市场整体环境等综合因素。公司聚焦核心主业，以务实举措稳步夯实公司核心投资价值。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800024070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SG9999014674.SGD","BK0028","002332"],"gpt_icon":0},{"id":"2586847782","title":"仙琚制药：以稳健经营和持续创新驱动价值呈现","url":"https://stock-news.laohu8.com/highlight/detail?id=2586847782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586847782?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:33","pubTimestamp":1764128025,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药11月26日在投资者关系平台上答复投资者关心的问题。股价受市场风格、行业状况、公司发展阶段、公司业绩等多种因素影响。公司深耕主业，稳健经营，并通过连续、稳定的分红政策，切实回报每一位投资者。面对近年来行业变化，我们将持续推动创新，以扎实的业绩、稳健的回报等多种方式，驱动公司价值呈现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600012399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0028","BK0239","002332"],"gpt_icon":0},{"id":"2585164512","title":"仙琚制药：黄体酮阴道缓释凝胶需补充临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2585164512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585164512?lang=zh_cn&edition=full","pubTime":"2025-11-21 08:54","pubTimestamp":1763686452,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药11月20日在投资者关系平台上答复投资者关心的问题。关注到公司申报的黄体酮阴道缓释凝胶已在CDE完成各项审评，祝贺公司有望实现该品种的首仿突破！据了解该产品目前尚未获批，预计需要进一步的补充临床研究。公司目前在研产品主要立足于高壁垒复杂制剂、吸入制剂、二类创新药，积极探索创新型新靶点。复杂制剂及新药研发具有不确定性，敬请投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100003846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002332","BK0028","SG9999014674.SGD"],"gpt_icon":0},{"id":"2584035336","title":"股市必读：仙琚制药(002332)股东户数5.1万户，较上期增加2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584035336","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584035336?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:01","pubTimestamp":1763424090,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2025年11月17日收盘，仙琚制药报收于9.81元，下跌1.51%，换手率1.58%，成交量15.51万手，成交额1.52亿元。资金流向11月17日主力资金净流入47.83万元；游资资金净流入648.43万元；散户资金净流出696.26万元。股东户数变动截至2025年11月13日，仙琚制药股东户数为5.1万户，较9月30日增加1411.0户，增幅2.85%；户均持股数量由上期的1.99万股减少至1.94万股，户均持股市值为19.32万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251118/31803001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002332","BK0028","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2584498556","title":"仙琚制药(002332)11月13日股东户数5.1万户，较上期增加2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584498556","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584498556?lang=zh_cn&edition=full","pubTime":"2025-11-17 17:37","pubTimestamp":1763372243,"startTime":"0","endTime":"0","summary":"证券之星消息，近日仙琚制药披露，截至2025年11月13日公司股东户数为5.1万户，较9月30日增加1411.0户，增幅为2.85%。在化学制药行业个股中，仙琚制药股东户数高于行业平均水平，截至11月13日，化学制药行业平均股东户数为3.47万户。从股价来看，2025年9月30日至2025年11月13日，仙琚制药区间涨幅为2.68%，在此期间股东户数增加1411.0户，增幅为2.85%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202511/17/20251117570064.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202511/17/20251117570064.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251117/31802015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002332","SG9999014674.SGD","BK0028","BK0239"],"gpt_icon":0},{"id":"2581771720","title":"华安证券：给予仙琚制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2581771720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581771720?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:45","pubTimestamp":1762357523,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,杨馥瑗近期对仙琚制药进行研究并发布了研究报告《业务短期承压，新产品获批在即》，给予仙琚制药买入评级。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有9家机构给出评级，买入评级8家，增持评级1家；过去90天内机构目标均价为12.78。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500041167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","600909"],"gpt_icon":0},{"id":"2581279793","title":"仙琚制药：意大利Newchem为原料药海外平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581279793?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:24","pubTimestamp":1762305848,"startTime":"0","endTime":"0","summary":"证券之星消息，仙琚制药(002332)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司在海外有布局了哪些平台？各个平台的作用是什么？谢谢仙琚制药回复：您好，感谢您的关注。公司的海外布局，主要有意大利Newchem公司作为公司原料药业务海外布局的生产、研发和销售平台。仙琚制药香港子公司主要做为公司未来海外制剂的拓展销售平台之一。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500006588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002332","SG9999014674.SGD"],"gpt_icon":0},{"id":"2580397239","title":"股市必读：仙琚制药（002332）10月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2580397239","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580397239?lang=zh_cn&edition=full","pubTime":"2025-11-03 05:11","pubTimestamp":1762117876,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，仙琚制药报收于9.47元，上涨1.28%，换手率1.48%，成交量14.56万手，成交额1.38亿元。董秘最新回复投资者： 董秘你好  公司大股东所持股票是否参与转融通交易？请正面核实后准确回答！当日关注点来自交易信息汇总：10月31日主力资金净流出998.22万元，散户资金净流入1546.23万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300001079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","BK0239","SG9999014674.SGD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769137651863,"stockEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":0.0343},{"period":"3month","weight":-0.023},{"period":"6month","weight":-0.1113},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":0.0388}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0517},{"period":"3month","weight":0.0436},{"period":"6month","weight":0.1472},{"period":"1year","weight":0.2828},{"period":"ytd","weight":0.0387}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江仙琚制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"50000人(较上一季度增加0.00%)","perCapita":"19691股","listingDate":"2010-01-12","address":"浙江省台州市仙居县仙药路1号","registeredCapital":"98920万元","survey":"　　浙江仙琚制药股份有限公司的主营业务是甾体原料药和制剂的研制、生产与销售。公司的主要产品是醋酸泼尼松、泼尼松龙、糠酸莫米松、雌二醇、炔雌醇、十一酸睾酮、米非司酮、醋酸甲羟孕酮、维库溴铵、舒更葡糖钠、戊酸雌二醇片、屈螺酮炔雌醇片、十一酸睾酮注射液、黄体酮胶囊(益玛欣)、复方庚酸炔诺酮注射液、左炔诺孕酮肠溶胶囊、米非司酮片、舒更葡糖钠注射液、注射用苯磺顺阿曲库铵、罗库溴铵注射液、注射用维库溴铵、甲磺酸罗哌卡因注射液、糠酸莫米松鼻喷雾剂、噻托溴铵粉雾剂、环索奈德气雾剂。","listedPrice":8.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仙琚制药,002332,仙琚制药股票,仙琚制药股票老虎,仙琚制药股票老虎国际,仙琚制药行情,仙琚制药股票行情,仙琚制药股价,仙琚制药股市,仙琚制药股票价格,仙琚制药股票交易,仙琚制药股票购买,仙琚制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}